CA3227287A1 - Heteroaryl compounds for treating huntington's disease - Google Patents
Heteroaryl compounds for treating huntington's disease Download PDFInfo
- Publication number
- CA3227287A1 CA3227287A1 CA3227287A CA3227287A CA3227287A1 CA 3227287 A1 CA3227287 A1 CA 3227287A1 CA 3227287 A CA3227287 A CA 3227287A CA 3227287 A CA3227287 A CA 3227287A CA 3227287 A1 CA3227287 A1 CA 3227287A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- triazol
- pyrrolo
- phenol
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203761P | 2021-07-30 | 2021-07-30 | |
| US63/203,761 | 2021-07-30 | ||
| PCT/US2022/038870 WO2023009816A1 (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227287A1 true CA3227287A1 (en) | 2023-02-02 |
Family
ID=83149486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227287A Pending CA3227287A1 (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240336613A1 (enExample) |
| EP (1) | EP4377317A1 (enExample) |
| JP (1) | JP2024528066A (enExample) |
| KR (1) | KR20240054264A (enExample) |
| CN (1) | CN118159539A (enExample) |
| AR (1) | AR126612A1 (enExample) |
| AU (1) | AU2022320725A1 (enExample) |
| CA (1) | CA3227287A1 (enExample) |
| CL (1) | CL2024000250A1 (enExample) |
| CO (1) | CO2024000890A2 (enExample) |
| CR (1) | CR20240043A (enExample) |
| IL (1) | IL310440A (enExample) |
| MX (1) | MX2024001417A (enExample) |
| PE (1) | PE20240929A1 (enExample) |
| TW (1) | TW202321247A (enExample) |
| WO (1) | WO2023009816A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| CN119451674A (zh) * | 2022-06-15 | 2025-02-14 | Ptc医疗公司 | 用于治疗亨廷顿病的杂环和杂芳基化合物 |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279688B2 (en) * | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
-
2022
- 2022-07-29 WO PCT/US2022/038870 patent/WO2023009816A1/en not_active Ceased
- 2022-07-29 CR CR20240043A patent/CR20240043A/es unknown
- 2022-07-29 AR ARP220102027A patent/AR126612A1/es unknown
- 2022-07-29 AU AU2022320725A patent/AU2022320725A1/en active Pending
- 2022-07-29 JP JP2024505314A patent/JP2024528066A/ja active Pending
- 2022-07-29 US US18/293,349 patent/US20240336613A1/en active Pending
- 2022-07-29 EP EP22761694.3A patent/EP4377317A1/en active Pending
- 2022-07-29 CA CA3227287A patent/CA3227287A1/en active Pending
- 2022-07-29 KR KR1020247003414A patent/KR20240054264A/ko active Pending
- 2022-07-29 PE PE2024000170A patent/PE20240929A1/es unknown
- 2022-07-29 IL IL310440A patent/IL310440A/en unknown
- 2022-07-29 MX MX2024001417A patent/MX2024001417A/es unknown
- 2022-07-29 CN CN202280066651.3A patent/CN118159539A/zh active Pending
- 2022-08-01 TW TW111128808A patent/TW202321247A/zh unknown
-
2024
- 2024-01-29 CL CL2024000250A patent/CL2024000250A1/es unknown
- 2024-01-30 CO CONC2024/0000890A patent/CO2024000890A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202321247A (zh) | 2023-06-01 |
| KR20240054264A (ko) | 2024-04-25 |
| US20240336613A1 (en) | 2024-10-10 |
| CR20240043A (es) | 2024-05-22 |
| WO2023009816A1 (en) | 2023-02-02 |
| AR126612A1 (es) | 2023-10-25 |
| CL2024000250A1 (es) | 2024-07-12 |
| MX2024001417A (es) | 2024-05-14 |
| AU2022320725A1 (en) | 2024-02-22 |
| IL310440A (en) | 2024-03-01 |
| JP2024528066A (ja) | 2024-07-26 |
| CO2024000890A2 (es) | 2024-04-29 |
| PE20240929A1 (es) | 2024-04-30 |
| EP4377317A1 (en) | 2024-06-05 |
| CN118159539A (zh) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12103926B2 (en) | Compounds for treating huntington's disease | |
| AU2019294478B2 (en) | Heterocyclic and heteroaryl compounds for treating Huntington's disease | |
| EP4377317A1 (en) | Heteroaryl compounds for treating huntington's disease | |
| AU2023241273A1 (en) | C26-linked rapamycin analogs as mTOR inhibitors | |
| CA3067592A1 (en) | Methods for treating huntington's disease | |
| AU2019294482A1 (en) | Heteroaryl compounds for treating Huntington's disease | |
| JP7799618B2 (ja) | ハンチントン病を処置するための化合物 | |
| AU2023320900A1 (en) | Compound based on isoindoline-substituted glutarimide backbone and use thereof | |
| EP4539841A2 (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| EA051950B1 (ru) | Гетероарильные соединения для лечения болезни хантингтона | |
| WO2025026422A1 (zh) | 芳基或杂芳基取代的戊二酰亚胺衍生物及其应用 | |
| HK40116823A (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| AU2024296347A1 (en) | Compounds based on thio-glutarimido isoindolinone skeleton and uses thereof | |
| NZ794019A (en) | Compounds for treating huntington's disease | |
| EA041957B1 (ru) | Соединения для лечения болезни гентингтона | |
| HK40043148A (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| HK40043148B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241015 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241121 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250616 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250617 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250620 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250623 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250703 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250716 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250716 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251110 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251222 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251222 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R114 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF METHOD OF CORRESPONDENCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251222 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260408 |
|
| R19 | Request for party data change rejected |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R19-R144 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED NOT COMPLIANT Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260408 |